<DOC>
	<DOCNO>NCT03009058</DOCNO>
	<brief_summary>During open label study patient receive IMM-101 conjunction recognise standard care metastatic unresectable cancer patient 's specific tumour type . The primary objective study provide safety data IMM-101 combination number select standard care regimen .</brief_summary>
	<brief_title>Study IMM 101 Combination With Standard Care Patients With Metastatic Unresectable Cancer</brief_title>
	<detailed_description>The study consist three phase - Screening , Treatment Maintenance . Patients provide informed consent , participate Screening period 28 day establish eligibility . Once eligibility confirm , patient enter Treatment Phase study . In Treatment Phase patient receive IMM-101 28 week . At Week 32 , Investigator consider patient ' best interest patient progress Maintenance Phase study continue dose every 4 week ( close interval permit due practical logistical consideration ) . Patients follow assessment safety , response treatment , survival , immunological marker 4.5 year .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Metastatic unresectable cancer consider physician indicate new line SOC list protocol Are ineligible disease specific clinical study IMM101 Have estimate life expectancy great 3 month ( Day 0 ) Give sign informed consent participation study Have Eastern Cooperative Oncology Group ( ECOG ) /World Health Organisation ( WHO ) Performance Status â‰¤2 Day 0 . Have adequate bone marrow , hepatic renal function Patient previously receive treatment IMM101 Patient currently part way course chemotherapy immunotherapy Patient receive concomitant treatment another investigational product Patient receive investigational drug within 4 week prior IMM 101 administration Patient significant cardiovascular disease Patient previous concurrent malignancy ( exclude adequately treat carcinoma situ cervix , basal cell carcinoma skin and/or non melanoma skin cancer , previous malignancy 5 year prior Screening sign recurrence ) Patient co exist active infection medical condition substantially increase risk associate patient 's participation study Patient uncontrolled hypercalcaemia Patient previously experience allergic reaction mycobacterial product . The patient history noninfectious pneumonitis require steroid current pneumonitis Patient receive live vaccine within 30 day plan start study medication Patient pregnant breast feed woman . Patient unwilling use medically acceptable , effective method contraception throughout treatment period least 6 month discontinuation treatment . Patient use depot corticosteroid 6 week initiation Screening Patient chronic use systemic corticosteroid within 2 week period first administration IMM101 Patient receive blood transfusion within 4 week prior Screening In opinion Investigator , patient unable unwilling comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Unresectable cancer</keyword>
	<keyword>pancreatic</keyword>
	<keyword>melanoma</keyword>
	<keyword>breast</keyword>
	<keyword>lung</keyword>
	<keyword>colorectal</keyword>
	<keyword>cholangio</keyword>
	<keyword>sarcoma</keyword>
</DOC>